Sutro Works Toward A Better Ovarian Cancer ADC
Readies Next Asset For The Clinic
Executive Summary
Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.